In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir | Zendy

Filippo Canducci | Zendy; Elisa Rita Ceresola | Zendy; Diego Saita | Zendy; Antonella Castagna | Zendy; Nicola Gianotti | Zendy; Mark Underwood | Zendy; Roberto Burioni | Zendy; Adriano Lazzarin | Zendy; Massimo Clementi | Zendy

Open Access

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir

Author(s) -

Filippo Canducci,

Elisa Rita Ceresola,

Diego Saita,

Antonella Castagna,

Nicola Gianotti,

Mark Underwood,

Roberto Burioni,

Adriano Lazzarin,

Massimo Clementi

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt220

Subject(s) - elvitegravir , raltegravir , dolutegravir , integrase inhibitor , virology , integrase , biology , phenotype , genetics , computational biology , virus , human immunodeficiency virus (hiv) , viral load , gene , antiretroviral therapy

The cross-resistance profiles of elvitegravir and dolutegravir on raltegravir-resistant variants is still controversial or not available in macrophages and lack extensive evaluations on wide panels of clonal variants. Thus, a complete evaluation in parallel with all currently available integrase inhibitors (INIs) was performed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research